Old Web
English
Sign In
Acemap
>
authorDetail
>
Thu Tran
Thu Tran
Stanford University
Antibody
Refractory
Lymphoma
Rituximab
Oncology
3
Papers
424
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
2019
Hematological Oncology
Ranjana H. Advani
Nancy L. Bartlett
Sonali M. Smith
Mark Roschewski
Leslie Popplewell
Ian W. Flinn
Graham P. Collins
Nilanjan Ghosh
Ann S. LaCasce
Adam S. Asch
Justin Kline
M. Kesevan
Thu Tran
Judith Lynn
Jie Huang
Balaji Agoram
Jens Peter Volkmer
Chris H. Takimoto
Mark P. Chao
A. Mehta
Show All
Source
Cite
Save
Citations (16)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
2018
The New England Journal of Medicine
Ranjana H. Advani
Ian W. Flinn
Leslie Popplewell
Andres Forero
Nancy L. Bartlett
Nilanjan Ghosh
Justin Kline
Mark Roschewski
Ann S. LaCasce
Graham P. Collins
Thu Tran
Judith Lynn
James Y. Chen
Jens Peter Volkmer
Balaji Agoram
Jie Huang
Ravindra Majeti
Irving L. Weissman
Chris H. Takimoto
Mark P. Chao
Sonali M. Smith
Show All
Source
Cite
Save
Citations (391)
Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.
2018
Journal of Clinical Oncology
Ranjana H. Advani
Ian W. Flinn
Leslie Popplewell
Andres Forero-Torres
Nancy L. Bartlett
Nilanjan Ghosh
Justin Kline
Thu Tran
Judith Lynn
James Y. Chen
Balaji Agoram
Jenny Huang
Chris H. Takimoto
Mark P. Chao
Sonali M. Smith
Show All
Source
Cite
Save
Citations (17)
1